Skip to main content
Premium Trial:

Request an Annual Quote

RXi Pharma Licenses Thermo Fisher's RNAi Sequences for Drug Programs

NEW YORK (GenomeWeb News) – CytRx subsidiary RXi Pharmaceuticals has licensed RNAi sequences from Thermo Fisher Scientific to a number of target genes for use in the development of therapeutic compounds for several common diseases, RXi said today.
 
Under the agreement, RXi will use RNAi sequences generated by Thermo Fisher Dharmacon’s sequence selection algorithm for its rxRNA compound program, which focuses on developing therapeutics for type 2 diabetes, obesity, neurology, and oncology.
 
RXi said the agreement covers around 100 RNAi sequences per target gene.
 
Financial terms of the agreement were not disclosed.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.